ML-SI3|cas:891016-02-7|西域试剂

ML-SI3,99.81%

产品编号：Bellancom-139426| CAS NO：891016-02-7| 分子式：C₂₃H₃₁N₃O₃S| 分子量：429.58

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-139426	￥1800.00	杭州北京（现货）
Bellancom-139426	￥2800.00	杭州北京（现货）
Bellancom-139426	￥5200.00	杭州北京（现货）
Bellancom-139426	￥8000.00	杭州北京（现货）
Bellancom-139426	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ML-SI3

产品介绍

ML-SI3 是一种 TRPML 通道抑制剂。ML-SI3 可阻断 TRPML1 和 TRPML2，IC₅₀s 分别为 4.7 µM 和 1.7 µM。ML-SI3 抑制溶酶体钙外流并阻断下游 TRPML1 介导的自噬。

生物活性

ML-SI3 is a TRPML Channel Inhibitor. ML-SI3 blocks TRPML1 and TRPML2 with IC₅₀s of 4.7 µM and 1.7 µM respectively. ML-SI3 prevents lysosomal calcium efflux and blocks downstream TRPML1-mediated induction of autophagy^[5].

体外研究

ML-SI3 (10 μM) inhibits ML-SA1-evoked Ca²⁺ signals in HeLa cells.
ML-SI3 (25-75 μM, 24h) disrupts tegumental integrity of adult schistosomes.
ML-SI3 (10 μM) blocks Rapamycin (HY-10219)-evoked I_TRPML1 in mimic of lysosomal lumen^[4].
ML-SI3 (3 µM, 6 h) abolishes the increase in both LC3II and p62 levels induced by hypoxia/reoxygenation (H/R) (4 h H/2 h R) in neonatal rat ventricular myocytes (NRVM)^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ML-SI3 (1.5 mg/kg, i.p., four times) attenuates I/R injury in mouse cardiomyocytes^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Myocardial Ischemia/reperfusion (I/R) injury mice^[5]
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection (i.p.), four times before and during the in vivo I/R (ischemia 30 min and reperfusion 1 day)
Result:	Restored the blocked autophagic fux in the cardiomyocytes subjected to I/R.

体内研究

ML-SI3 (1.5 mg/kg, i.p., four times) attenuates I/R injury in mouse cardiomyocytes^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Myocardial Ischemia/reperfusion (I/R) injury mice^[5]
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection (i.p.), four times before and during the in vivo I/R (ischemia 30 min and reperfusion 1 day)
Result:	Restored the blocked autophagic fux in the cardiomyocytes subjected to I/R.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (116.39 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3279 mL	11.6393 mL	23.2786 mL
5 mM	0.4656 mL	2.3279 mL	4.6557 mL
10 mM	0.2328 mL	1.1639 mL	2.3279 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。